Adocia Announces Its Financial Publication Schedule for 2026
The Lyon-based biopharmaceutical company Adocia has announced the dates for its financial publications and general assembly for the fiscal year 2026.
Quarterly Financial Reporting
According to the press release, the group will publish its fourth quarter 2025 revenue on February 24, 2026. The subsequent three quarters of 2026 will be reported on May 12, July 23, and October 29, 2026. This quarterly rhythm is part of the financial communication obligations for companies listed on Euronext Paris.
Annual and Semi-Annual Results
The company indicates that its annual results for 2025 will be revealed on April 21, 2026. The semi-annual results as of June 30, 2026, will be published on September 24, 2026. The general assembly of shareholders is scheduled for June 3, 2026. The company specifies that all regulated information is available on its website in the investors' section.
Company Profile
According to the press release, Adocia employs about 80 staff members and has a portfolio of drug candidates derived from four proprietary technology platforms. Based in Lyon, the company focuses on developing therapeutic solutions for the treatment of diabetes and obesity. The group holds more than 25 patent families and is listed on the Euronext Paris market under the ticker ADOC.
